Cell Biotech CoXKRX:049960 +0.46%80 Net Cash per Share is ₩12,323.37 as of Mar. 2026, which is 100% below its 10-year median of 2.26. GuruFocus rates XKRX:049960 with a GF Score™ of 80/100 and a GF Value™ of ₩14,595.17 (Fairly Valued). The stock has 1 warning sign investors should review. Among 810 Biotechnology companies, Cell Biotech Co ranks better than 90.12% on this metric.
The historical rank and industry rank for Cell Biotech Co's Net Cash per Share or its related term are showing as below:
XKRX:049960'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.02 Med: 2.26 Max: 11.24
Current: 1.23
During the past 13 years, the highest Price-to-Net-Cash Ratio of Cell Biotech Co was 11.24. The lowest was 1.02. And the median was 2.26.
XKRX:049960's Price-to-Net-Cash is ranked better than 90.12% of 810
companies
in the Biotechnology industry
Industry Median: 5.15
vs XKRX:049960: 1.23
Cell Biotech Co (XKRX:049960) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Cell Biotech Co Net Cash per Share Related Terms
Cell Biotech Co Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Cell Biotech Co's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:049960 vs VRTX, REGN, ALNY: Net Cash per Share Comparison
For the Biotechnology subindustry, Cell Biotech Co's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cell Biotech Co Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cell Biotech Co's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Cell Biotech Co's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Cell Biotech Co's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Cash per Share of ₩12,323.37 mean?
Cell Biotech Co (XKRX:049960) has a Net Cash per Share of ₩12,323.37 as of Mar. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Cell Biotech Co and its competitors. This is 545182% above median its historical median of 2.26. Over the past decade, Cell Biotech Co's Net Cash per Share has ranged from 1.02 to 11.24. According to the industry distribution chart, Cell Biotech Co ranks #80 out of 810 companies in the Biotechnology industry, placing it in the top 9.9%.
Is Cell Biotech Co's Net Cash per Share too high?
Cell Biotech Co's current Net Cash per Share of ₩12,323.37 is 545182% above median its 10-year median of 2.26. Over the past 10 years, this metric has ranged from a low of 1.02 to a high of 11.24. Based on the distribution chart, Cell Biotech Co ranks #80 out of 810 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cell Biotech Co has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cell Biotech Co's Net Cash per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cell Biotech Co ranks #80 out of 810 companies for Net Cash per Share. This places Cell Biotech Co in the top 10% of its industry — outperforming the majority of peers. The industry median Net Cash per Share is 5.15. Historically, Cell Biotech Co's own Net Cash per Share has ranged from 1.02 to 11.24 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.15, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Cell Biotech Co and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cell Biotech Co's current Net Cash per Share is ₩12,323.37, which is 545182% above median its own 10-year median of 2.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Cell Biotech Co (XKRX:049960) is currently considered Fairly Valued. The stock's GF Value™ is ₩14,595.17, compared to a current price of ₩15,200.00 — trading 4.1% above its estimated fair value. The current Net Cash per Share is ₩12,323.37, which is 545182% above median its 10-year median of 2.26. Cell Biotech Co's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Cell Biotech Co (XKRX:049960), the current Net Cash per Share is ₩12,323.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cell Biotech Co (XKRX:049960) Overvalued in 2026?
Based on GuruFocus' analysis, Cell Biotech Co stock appears to be overvalued.
The current stock price of ₩15,200.00 is trading 4.1% above its estimated GF Value™ of ₩14,595.17.
GuruFocus considers Cell Biotech Co to be Fairly Valued.
Key valuation signals for XKRX:049960:
Net Cash per Share: ₩12,323.37 (545182% above median its 10-year median of 2.26)
GF Value™: ₩14,595.17 vs. price of ₩15,200.00 (4.1% above fair value)
No single metric tells the full story. See the XKRX:049960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cell Biotech Co Ltd is a specialized biotech company. It is engaged in the fermentation and coating technology development as well as manufacturing probiotics and lactic acid bacteria. The key product consists Probiotic DUOLAC, Nutra DUOLAC, LACTOClear, and LAB2PRO. The company distributes its products within domestic market and to overseas markets.
80GF Score
Get the complete analysis for XKRX:049960
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:049960 has been successfully added to your 
